Glioblastoma
44 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Accelerated Hypofractionated Radiation Therapy for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Allogeneic genetically modified gamma-delta T cells for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Anti-PD-1 monoclonal antibody + LCB84 for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for glioblastoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for glioblastoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autologous genetically modified gamma-delta T cells for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brain surgery + RETIFANLIMAB + RAGIFILIMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brain surgery + SRS + RETIFANLIMAB + RAGIFILIMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX-471 + Tovecimig for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dose-escalated radiation therapy for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dose-intensified Accelerated Photon Beam Radiation Therapy for glioblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dose-intensified Photon Beam Radiation Therapy for glioblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluzoparib with Temozolomide for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hypofractionated re-irradiation + MANNITOL + Cetuximab for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IA Carboplatin + IA Caelyx for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IA Carboplatin + IA Etoposide Phosphate for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IDH1-vac for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Idroxioleate Sodium for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ipatasertib + atezolizumab for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JBI-778 for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JK-1201I + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LCB84 for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lenvatinib for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-dose Radiotherapy + SINTILIMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M032 + PEMBROLIZUMAB for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Magnetic Resonance Imaging + Biospecimen Collection + Lumbar Puncture + Radiation Therapy + Dabrafenib Mesylate + TRAMETINIB DIMETHYL SULFOXIDE for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Maximal surgical resection + Radical radiotherapy + Stupp regimen (oral temozolomide) + THIOTEPA for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Niraparib for glioblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Onfekafusp alfa for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Optune System + PEMBROLIZUMAB + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Perillyl alcohol for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Radiodynamic therapy + AMINOLEVULINIC ACID HYDROCHLORIDE for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sacituzumab govitecan for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Selinexor for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Srs + retifanlimab + ragifilimab for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Subventricular Zone radiation for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Temozolomide for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tovecimig for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vebreltinib for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |